AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24743802 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 156
Study 24743802 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg)
Number of subjects: 156
Study 24743802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 22139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative clinical risk (calculated from pre-HCT neuropsychological risk factors, HCT-related risk factors, and post-HCT complications)
Number of subjects: 278
Study 22139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative clinical risk
Number of subjects: 278
Study 22139882 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 278
Study 20975066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (SHDCT) before myeloablative therapy
Number of subjects: 284
Study 20975066 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (A) with myeloablative therapy with carmustine, BEAM followed by PBSCT
Number of subjects: 284
Study 18925347 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naive group
Number of subjects: 1362
Study 18925347 — intervention group
Group type: EXPERIMENTAL
Intervention: One to two prior treatments group
Number of subjects: 1362
Study 18925347 — intervention group
Group type: COMPARATOR
Intervention: Three or more prior treatments group
Number of subjects: 1362
Study 15847747 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg daily for 3 months
Number of subjects: 98
Study 15847747 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5.2 mg daily for 3 months
Number of subjects: 98
Study 15847747 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 98
Study 15847747 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 98
Study 12059949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs (ZDV/3TC, d4T/3TC, or d4T/ddI)
Number of subjects: 93
Study 12059949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir/Indinavir at 400/400 mg BID in combination with two NRTIs
Number of subjects: 93
Study 10686859 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamelon (E)
Number of subjects: 18
Study 10686859 — intervention group
Group type: COMPARATOR
Intervention: Crest (C)
Number of subjects: 18
Study 10686859 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride placebo toothpaste (P)
Number of subjects: 18
Study 7851596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm morphology assessment using strict criteria (Tygerberg or Norfolk classification)
Number of subjects: 163
Study 7851596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm migration ability in vivo under hormonally controlled conditions for the cervical mucus (CM) quality
Number of subjects: 163
Study 7851596 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed sperm‐CM penetration test performed with CM of patients' partners
Number of subjects: 163
Study 7851596 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity of spermatozoa with normal head morphology
Number of subjects: 163
Study 1756263 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU), 60 mg IV once a week for 6 weeks
Number of subjects: 517
Study 1756263 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg/sqm P.O. on days 1‐14, methotrexate 40 mg/sqm IV on day 1 and 8, fluorouracil 600 mg/sqm IV on day 1 and 8; monthly cycle, for 6 months)
Number of subjects: 517
Study 1756263 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU)
Number of subjects: 517
Study 6802412 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day course of amoxycillin (25 mg/kg daily)
Number of subjects: 84
Study 6802412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day course of amoxycillin (25 mg/kg daily)
Number of subjects: 84
Study 31968351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil implantation
Number of subjects: 39
Study 31968351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil implantation (responders)
Number of subjects: 39
Study 31968351 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial coil implantation (non-responders)
Number of subjects: 39
Study 31976336 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT) for 60 minutes at 70% of HRpeak
Number of subjects: 26
Study 31976336 — intervention group
Group type: COMPARATOR
Intervention: Interval exercise training (INT) for 60 minutes, alternating 3 minutes at 90% and 50% HRpeak
Number of subjects: 26
Study 31976336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CONT and INT
Number of subjects: 26
Study 27000142 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor monitoring using wireless motion sensor technology
Number of subjects: 40
Study 27000142 — intervention group
Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 40
Study 27000142 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor monitoring
Number of subjects: 40
Study 27138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS over left dorsolateral prefrontal cortex (n=25)
Number of subjects: 47
Study 27138827 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=22)
Number of subjects: 47
Study 23419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114
Study 23419803 — intervention group
Group type: COMPARATOR
Intervention: Contact lens treatment
Number of subjects: 114
Study 23419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger cohort (<49 days at surgery)
Number of subjects: 114
Study 23419803 — intervention group
Group type: EXPERIMENTAL
Intervention: Older cohort (≥ 49 days at surgery)
Number of subjects: 114
Study 21538069 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 21
Study 21538069 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 21
Study 21538069 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 21
Study 19142090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 19142090 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 19142090 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study 17537209 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator implant
Number of subjects: 204
Study 17537209 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 204
Study 15530197 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized multi-institutional research protocol studying reintubation rate using three methods for weaning from mechanical ventilation.
Number of subjects: 217
Study 15530197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing session with five symposia and short oral presentations.
Number of subjects: 217
Study 15530197 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual admissions in pediatric intensive care units.
Number of subjects: 217
Study 15530197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate in pediatric intensive care units.
Number of subjects: 217
Study 11474345 — intervention group
Group type: EXPERIMENTAL
Intervention: C (5 mg x kg(‐1))
Number of subjects: 24
Study 11474345 — intervention group
Group type: EXPERIMENTAL
Intervention: E (1 mg x kg(‐1))
Number of subjects: 24
Study 11474345 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 24
Study 11474345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study 10921014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal perfusion chemotherapy (IPPC) with 1 g 5-Fu and 10 mg MMC in warm sterile water, once per day for 6 days.
Number of subjects: 102
Study 10921014 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 1 g 5-Fu and 8 mg MMC, once per day for 6 days (Control group).
Number of subjects: 102
Study 7977595 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 2.5% ophthalmic solution
Number of subjects: 100
Study 7977595 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate 1% ophthalmic solution
Number of subjects: 100
Study 7977595 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 0.5% ointment
Number of subjects: 100
Study 2596940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) plus potassium supplement (20 mmol/d)
Number of subjects: 447
Study 2596940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) plus potassium supplement (40 mmol/d)
Number of subjects: 447
Study 2596940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/d) with triamterene (75 mg/d)
Number of subjects: 447
Study 31345163 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1500 mg
Number of subjects: 50
Study 31345163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28469045 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE and Trans-Theoretical models, duration: 2 months education and 6 months follow-up.
Number of subjects: 344
Study 28469045 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE and Trans-Theoretical models.
Number of subjects: 344
Study 28469045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 344
Study 25476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable-syringe jet injector (DSJI)
Number of subjects: 582
Study 25476584 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe (NS)
Number of subjects: 582
Study 25476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DSJI and NS
Number of subjects: 582
Study 24453924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphurous thermal water inhalation
Number of subjects: 40
Study 24453924 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline inhalation
Number of subjects: 40
Study 21960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 70
Study 21960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 0.63 mg
Number of subjects: 70
Study 21960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 1.25 mg
Number of subjects: 70
Study 21960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide
Number of subjects: 70
Study 19120892 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, and GAT for 7 days (RAG)
Number of subjects: 14
Study 19120892 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole and amoxicillin (RA)
Number of subjects: 14
Study 16646120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mental activity (daily memorization of prose passages and demanding mental arithmetic) for 2 weeks
Number of subjects: 10
Study 16646120 — intervention group
Group type: COMPARATOR
Intervention: Convenience control group (no intervention)
Number of subjects: 10
Study 14618551 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive language impairment
Number of subjects: 315
Study 14618551 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptive language difficulties
Number of subjects: 315
Study 10826457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study 10826457 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1292
Study 8656385 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 176
Study 2003591 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg iv bolus)
Number of subjects: 19
Study 2003591 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 19
Study 7025090 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylglucamine metrizoate (Isopaque Cerebral, 280 mg I/mI)
Number of subjects: 170
Study 7025090 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide (Amipaque, 280 mg I/mI)
Number of subjects: 170
Study 29187584 — intervention group
Group type: EXPERIMENTAL
Intervention: BsAb-5 (bispecific antibody targeting c-MET and CTLA-4)
Number of subjects: 0
Study 29187584 — intervention group
Group type: EXPERIMENTAL
Intervention: BsAb-5
Number of subjects: 0
Study 27563831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise therapy (20-week individualized, comorbidity-adapted exercise program consisting of aerobic and strength training and training of daily activities)
Number of subjects: 126
Study 27563831 — intervention group
Group type: COMPARATOR
Intervention: Current medical care for knee OA (control group)
Number of subjects: 126
Study 25819948 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (specifying when, where, and how to act)
Number of subjects: 0
Study 24209639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours (F2) with 200 ml of clear liquids ingested 2 hours before the procedure
Number of subjects: 98
Study 24209639 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 8 hours (F8)
Number of subjects: 98
Study 24209639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 2 hours (F2)
Number of subjects: 98
Study 21468621 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel alloy
Number of subjects: 15
Study 21468621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-free alloy
Number of subjects: 15
Study 21468621 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium alloy
Number of subjects: 15
Study 21468621 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 19954546 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise group (specific motor relearning and graded activity exercises)
Number of subjects: 176
Study 19954546 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational booklet on whiplash)
Number of subjects: 176
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP1 (three sets of five jumps with extra load)
Number of subjects: 12
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP2 (two sets of four reps at 80% of 1RM(PS) and two sets of two reps at 85% of 1RM(PS))
Number of subjects: 12
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP3 (two sets of four reps at 80% of 1RM(PS), two sets of two reps at 90% of 1RM(PS), and two sets of one rep at 95% of 1RM(PS))
Number of subjects: 12
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP4 (three sets of five DJs)
Number of subjects: 12
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP5 (specified warm-up for a volleyball match)
Number of subjects: 12
Study 17394010 — intervention group
Group type: EXPERIMENTAL
Intervention: WP6 (three sets of five reps at 30% 1RM(PS))
Number of subjects: 12
Study 17394010 — intervention group
Group type: COMPARATOR
Intervention: No active warm-up (control condition)
Number of subjects: 12
Study 15522911 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 28 days
Number of subjects: 29
Study 15522911 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-obese subjects)
Number of subjects: 29
Study 11783048 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 87
Study 9848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid therapy (short-time)
Number of subjects: 99
Study 9848065 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid therapy (long-time)
Number of subjects: 99
Study 9848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy (bolus group)
Number of subjects: 99
Study 9848065 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy (tapering group)
Number of subjects: 99
Study 9848065 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tyndallometry
Number of subjects: 99
Study 7584303 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exposure to three activities during the reactivation session
Number of subjects: 0
Study 7584303 — intervention group
Group type: COMPARATOR
Intervention: Control group (not reminded or did not engage in the activities)
Number of subjects: 0
Study 2576886 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally
Number of subjects: 58
Study 2576886 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally in group A (procto-anal)
Number of subjects: 58
Study 2576886 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) administered epidurally in group B (inguino-crural)
Number of subjects: 58
Study 2576886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 1001205 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate and phenformin
Number of subjects: 15
Study 31120614 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine (0.2% at 4‐6 ml/h)
Number of subjects: 96
Study 31120614 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 96
Study 28012403 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy based on analog insulin (detemir/aspart)
Number of subjects: 114
Study 28012403 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy based on human insulin (NPH/regular)
Number of subjects: 114
Study 28012403 — intervention group
Group type: EXPERIMENTAL
Intervention: Analog insulin treatment
Number of subjects: 114
Study 28012403 — intervention group
Group type: COMPARATOR
Intervention: Human insulin treatment
Number of subjects: 114
Study 28012403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (analog and human insulin)
Number of subjects: 114
Study 26046455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with fentanyl 5 μg/mL
Number of subjects: 402
Study 26046455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with fentanyl 5 μg/mL and epinephrine 5 μg/mL
Number of subjects: 402
Study 23330900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements by students
Number of subjects: 10
Study 23330900 — intervention group
Group type: COMPARATOR
Intervention: Physical examination by physicians
Number of subjects: 10
Study 23330900 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance in student measurements
Number of subjects: 10
Study 23330900 — intervention group
Group type: COMPARATOR
Intervention: Variance in physician measurements
Number of subjects: 10
Study 21789429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day of soy protein
Number of subjects: 27
Study 21789429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day of soy protein plus fibers
Number of subjects: 27
Study 21789429 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg/day of animal protein
Number of subjects: 27
Study 19247779 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during anesthesia induction
Number of subjects: 14
Study 19247779 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 14
Study 19247779 — intervention group
Group type: COMPARATOR
Intervention: Parental presence plus midazolam
Number of subjects: 14
Study 19247779 — intervention group
Group type: COMPARATOR
Intervention: Parental presence plus video game
Number of subjects: 14
Study 19247779 — intervention group
Group type: COMPARATOR
Intervention: No parental presence
Number of subjects: 14
Study 17302782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (target hematocrit level of 28%)
Number of subjects: 40
Study 15220950 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meal frequency (6 occasions per day)
Number of subjects: 9
Study 15220950 — intervention group
Group type: COMPARATOR
Intervention: Irregular meal frequency (3-9 meals/day)
Number of subjects: 9
Study 11437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer 5-ASA formulations
Number of subjects: 0
Study 11437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosages of mesalazine
Number of subjects: 0
Study 11437696 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA-containing preparations
Number of subjects: 0
Study 11437696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosalicylates
Number of subjects: 0
Study 9678070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Number of subjects: 18
Study 9678070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Number of subjects: 18
Study 9678070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (0.28 mg and 0.32 mg ethinylestradiol)
Number of subjects: 18
Study 8026301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 1.00 g/kg
Number of subjects: 0
Study 8026301 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.50 g/kg
Number of subjects: 0
Study 8026301 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.75 g/kg
Number of subjects: 0
Study 2530317 — intervention group
Group type: COMPARATOR
Intervention: Intravenous floxuridine (IV FUDR)
Number of subjects: 143
Study 2530317 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic intraarterial floxuridine (IA FUDR)
Number of subjects: 143
Study 2530317 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IV FUDR and IA FUDR
Number of subjects: 143
Study 1027635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortagesic
Number of subjects: 0
Study 1027635 — intervention group
Group type: COMPARATOR
Intervention: Paramol 118
Number of subjects: 0
Study 31475798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 19220
Study 31475798 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 19220
Study 29049935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT) 36 IU daily for 4-6 weeks
Number of subjects: 0